The landscape of dementia prognosis has developed dramatically with the advent of innovative biomarkers, together with amyloid PET scans, tau imaging, and blood-primarily based exams which will detect Alzheimer's pathology decades before signs and symptoms emerge. Although these technological improvements characterize extraordinary development in u